NewsBenzingaClimb Bio And Mabworks Report Phase 1 Data Supporting Quarterly CLYM116/MIL116 Dosing For IgA Nephropathy; Phase 3 Trial Expected In 2027 Climb Bio And Mabworks Report Phase 1 Data Supporting Quarterly CLYM116/MIL116 Dosing For IgA Nephropathy; Phase 3 Trial Expected In 2027 Benzinga 2026.10.23 20:01 (GMT+0) Open on Benzinga Other news Morgan Stanley Maintains Equal-Weight on W.W. Grainger, Raises Price Target to $1590 SpaceX's IPO Playbook Could Give Anthropic A $19B Buying Cushion—But There's A Catch What Is Going on With CoreWeave Stock on Monday? Morgan Stanley Maintains Underweight on Virgin Galactic Holdings, Lowers Price Target to $1.75 Occidental Petroleum Analyst Turns Bearish Due To Limited Volume Upside If You Invested $1000 In Monster Beverage Stock 5 Years Ago, You Would Have This Much Today